Skip to main content

ULTRA-DD

Innovative Medicines Initiative LogoEfpia logoEuropean Commission Research and Innovation logo

Search

  • Overview
    • Objectives and disease focus
    • Deliverables
      • Executive Summary 2020 Report
      • Executive Summary 2019 Report
      • Executive Summary 2018 Report
    • Organisation
      • Scientific Committee
      • Leadership
    • Participants
    • News
    • Contact
  • Tissue Platforms
    • Diseases
    • Cell Assay Datasets
  • Probes
    • Chemical Probes
    • Biological probes
  • Antibodies
  • Structures
  • ChromoHub
  • Publications

Bromodomain Inhibitors are Potent Epigenetic Regulators of Catabolic Gene Expression in Human Osteoarthritic Chondrocytes.

  • Read more about Bromodomain Inhibitors are Potent Epigenetic Regulators of Catabolic Gene Expression in Human Osteoarthritic Chondrocytes.

de Andrés, M.C., Madhusudan, N., Bountra, C., Oppermann, U., Oreffo, R.O. (2018). Bromodomain Inhibitors are Potent Epigenetic Regulators of Catabolic Gene Expression in Human Osteoarthritic Chondrocytes. Osteoarthritis and Cartilage, 26(1), S154.

TP-064, a Potent and Selective Small Molecule Inhibitor of PRMT4 for Multiple Myeloma.

  • Read more about TP-064, a Potent and Selective Small Molecule Inhibitor of PRMT4 for Multiple Myeloma.

Nakayama, K., Szewczyk, M. M., Dela Sena, C., Wu, H., Dong, A., Zeng, H., … Brown, P. J. (2018). TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma. Oncotarget, 9(26), 18480–18493.

Donated Chemical Probes for Open Science

  • Read more about Donated Chemical Probes for Open Science

Müller, S., Ackloo, S., Arrowsmith, C. H., Bauser, M., Baryza, J. L., Blagg, J., … Mueller-Fahrnow, A. (2018). Donated chemical probes for open science. eLife, 7, e34311.

LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity.

  • Read more about LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity.

Bonday, Z.Q., Cortez, G.S., Grogan, M.J., Antonysamy, S., Weichert, K., Bocchinfuso, W.P., ... Campbell, R.M. (2018). LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity. ACS Medicinal Chemistry Letters, 9(7), 612-617.

DOT1L Inhibition Attenuates Graft-Versus-Host Disease by Allogeneic T Cells in Adoptive Immunotherapy Models.

  • Read more about DOT1L Inhibition Attenuates Graft-Versus-Host Disease by Allogeneic T Cells in Adoptive Immunotherapy Models.

Kagoya, Y., Nakatsugawa, M., Saso, K., Guo, T., Anczurowski, M., Wang, C. H., … Hirano, N. (2018). DOT1L Inhibition Attenuates Graft-Versus-Host Disease by Allogeneic T Cells in Adoptive Immunotherapy Models. Nature Communications, 9(1), 1915.

BET Bromodomain Ligands: Probing the WPF Shelf to Improve BRD4 Bromodomain Affinity and Metabolic Stability.

  • Read more about BET Bromodomain Ligands: Probing the WPF Shelf to Improve BRD4 Bromodomain Affinity and Metabolic Stability.

Jennings LE, Schiedel M, Hewings DS, Picaud S, Laurin CMC, Bruno PA, ... Conway SJ. (2018). BET Bromodomain Ligands: Probing the WPF Shelf to Improve BRD4 Bromodomain Affinity and Metabolic Stability. Bioorganic & Medicinal Chemistry, 26(11), 2937-2957.

What Is the BET on Solid Tumors?

  • Read more about What Is the BET on Solid Tumors?

Filippakopoulos P. (2018). What Is the BET on Solid Tumors? Journal of Clinical Oncology.

Development, Optimization and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4-d]pyrrolo[2,3-b]pyridine Scaffold.

  • Read more about Development, Optimization and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4-d]pyrrolo[2,3-b]pyridine Scaffold.

Forster, M., Chaikuad, A., Dimitrov, T., During E, Holstein J, Berger BT, ... Laufer SA. (2018). Development, Optimization and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4-d]pyrrolo[2,3-b]pyridine Scaffold. Journal of Medicinal Chemistry, 61(12), 5350-5366.

A Bench-Stable Transfer Reagent for the Synthesis of Trifluoromethyl-sulfonimidamides from Sulfinamides.

  • Read more about A Bench-Stable Transfer Reagent for the Synthesis of Trifluoromethyl-sulfonimidamides from Sulfinamides.

Wright, M., Martinez-Lamenca, C., Leenaerts, J.E., Brennan, P.E., Trabanco, A.A., Oehlrich, D. (2018). A Bench-Stable Transfer Reagent for the Synthesis of Trifluoromethyl-sulfonimidamides from Sulfinamides. Journal of Organic Chemistry, 83(16), 9510-9516.

SATurn: A Modular Bioinformatics Framework for the Design of Robust Maintainable Web-Based and Standalone Applications

  • Read more about SATurn: A Modular Bioinformatics Framework for the Design of Robust Maintainable Web-Based and Standalone Applications

Damerell, D. R., Strain-Damerell, C., Garsot, S., Joyce, S. P., Barrett, P., & Marsden, B. D. (2018). SATurn: A Modular Bioinformatics Framework for the Design of Robust Maintainable Web-Based and Standalone Applications. Bioinformatics (Oxford, England), 35(2), 349–351.

Pagination

  • Previous page ‹‹
  • Next page ››
Subscribe to 2018
The ULTRA-DD project is supported by the Innovative Medicines Initiative Joint Undertaking (IMI JU) under grant agreement n° [115766], resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. This website reflects only the author’s views and neither IMI nor the European Commission is liable for any use that may be made of the information contained therein.
This website is licensed under a CC-BY licence | Accessibility